Antares Pharma Announces Partner Idorsia Initiates the Phase 3 Study With Selatogrel for Acute Myocardial Infarction

NEXT STORY
Next Generation Sequencing Market Worth US$30,424.3 Million by 2031: Visiongain Research Inc.
PREV STORY
Pomerleau and the MUHC Foundation work toward revolutionizing cancer care across Canada
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week

author_avatar
NASDAQ Market News

European Medicines Agency Accepts GBT’s Marketing Authorization Application (MAA) for Oxbryta® (voxelotor) for the Treatment of Hemolytic Anemia in Sickle Cell Disease

author_avatar
NASDAQ Market News

Polyphor receives CARB-X award of up to USD 18.44 million to support development of new antibiotic program

author_avatar
NASDAQ Market News